| Quote | Spy ACOR NEW ![]() |
Message Board | |||||
|
Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders. |
|
Acorda Thera Posts Q3 Loss of $0.51, 8c Better than Estimates
ACOR Linked by StreetInsider - November 03, 07:56AM from (www.streetinsider.com) more ...
Acorda Therapeutics Reports Third Quarter 2009 Financial Results
ACOR Linked by BusinessWire - November 03, 06:00AM from (www.businesswire.com) Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter of 2009. “The more ...
Acorda Therapeutics to Host Conference Call to Report Third Quarter 2009 Financial Results on November 3, 2009
ACOR Linked by BusinessWire - October 27, 07:00AM from (www.businesswire.com) Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it will host a conference call and live audio webcast to report more ...
Analyst upgrades, downgrades and initiations: ACOR, BHI, HAL, LAZ, SLB, TRV ...
HES HAL TSO TRV SLB BHI BJS NFX IVZ PCG ACOR ATI CBI HST AZ LAZ CPX PBR Linked by BloggingStocks - October 15, 11:43AM from (www.pheedcontent.com) Analyst upgrades: Citigroup upgraded Schlumberger (NYSE: SLB) to Buy from Hold on valuation and the company's more ...
Top 10 Analyst Upgrades, Downgrades, Initiations
IP PETD WDC SPWRA ASML ACOR OPEN TRW LAZ PBR Linked by 24/7 Wall St. - October 15, 08:27AM from (feedproxy.google.com) These are this morning's top 10 pre-market analyst upgrades, downgrades, and initiations which we have seen early from Wall Street research firms: more ...
Top Day Trader Alerts
SVNT SPPI AVNR ACOR TSM INFY Linked by 24/7 Wall St. - October 09, 08:57AM from (feedproxy.google.com) These are this Friday morning's top day trader and active trader alert stocks. We have provided a link through to VSInvestor.com more ...
Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
ACOR Linked by BusinessWire - October 09, 08:30AM from (www.businesswire.com) Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has posted on its more ...
Top Analyst Upgrades
CVS CCE CREE ACOR SVVS ICE Linked by 24/7 Wall St. - August 05, 07:57AM from (feedproxy.google.com) These are the top pre-market analyst upgrades and positive research calls we have seen from Wall Street early this Wednesday morning: more ...
Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development
ACOR Linked by BusinessWire - August 05, 07:00AM from (www.businesswire.com) Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ruhi Khan has been named Vice President, Business Development, more ...
Acorda Therapeutics Reports Second Quarter 2009 Financial Results
ACOR Linked by BusinessWire - August 04, 06:00AM from (www.businesswire.com) Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter of 2009. more ...
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2009 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF. |
|